Question: Once‑daily teriparatide (Forteo®) injection results in:

Answer Choices:\n\nA. ↑ renal excretion of pyrophosphate B. ↑ osteoblast activity & bone formation C. ↑ osteoclast activity & bone resorption D. ↑ renal excretion of calcium

Answer:\nB

 

Question: Which germ layer would be affected by folic acid supplementation?

Answer Choices:\n\nA. Ectoderm B. Gastrulation C. Mesoderm D. Endoderm

Answer:\nA

 

Question: Which is recognized as an undesirable effect of some early generation progestins?

Answer Choices:\n\nA. Androgenic activity B. Anti-progestogenic activity C. Estrogenic activity D. Anti-glucocorticoid activity

Answer:\nA

 

Question: Return to fertility is most likely to be delayed with which contraceptive method?

Answer Choices:\n\nA. ParaGard® IUD B. Depo-Provera® C. Xulane® patch D. Combined oral contraceptives

Answer:\nB

 

Question: A postmenopausal woman with a uterus wants HT for vasomotor symptoms. Which is best to minimize endometrial risk?

Answer Choices:\n\nA. Estrace® (oral estradiol) + Osphena® B. Duavee® (conjugated estrogens/bazedoxifene) C. Vivelle-Dot® (transdermal estradiol) D. Femring® (vaginal estradiol ring) E. Prometrium® (oral micronized progesterone)

Answer:\nB

 

Question: A woman on a COC has spotting in the first week of active tablets, resolving in week 2, for 6 months. Best recommendation?

Answer Choices:\n\nA. Decrease estrogen content B. No change; wait longer C. Increase estrogen content D. Switch to a COC with iron tablets

Answer:\nC

 

Question: A 32-year-old (2 vaginal deliveries) is starting a new combined oral contraceptive. Which initiation method is most appropriate?

Answer Choices:\n\nA. Sunday start + backup sponge for 7 days B. Quick start + backup cervical cap for 7 days C. Quick start, backup optional/not required D. First-day start, backup optional/not required

Answer:\nB

 

Question: Which treatment has shown increased effectiveness in ER+/HER2- breast cancer if BRCA1/2 germline mutations are present?

Answer Choices:\n\nA. Capecitabine (Xeloda®) B. Olaparib (Lynparza®) C. Alpelisib (Piqray®) D. Vinorelbine (Navelbine®)

Answer:\nB

 

Question: The primary role of the estrogen component in oral contraception is to:

Answer Choices:\n\nA. Provide better cycle control B. Counter progestin toxicity C. Protect the endometrium D. Prevent follicular maturation

Answer:\nA

 

Question: Which factor(s) increase breast cancer risk? (Select ALL)

Answer Choices:\n\nA. Late menarche B. Obesity C. Use of HRT D. Early menopause

Answer:\nB, C

 

Question: Microtubule-targeted agents (ixabepilone, vinorelbine) are associated with which adverse effect?

Answer Choices:\n\nA. Gingival hyperplasia B. Peripheral neuropathy C. Cardiotoxicity D. Hemorrhagic cystitis

Answer:\nB

 

Question: In which ovarian phase do high estrogen levels provide positive feedback to the hypothalamus?

Answer Choices:\n\nA. Early follicular B. Late follicular C. Early luteal D. Late luteal

Answer:\nB

 

Question: Put these menopause-related events in order (1: FSH/LH ↑, 2: Osteoporosis risk ↑, 3: Estrogen/progesterone ↓, 4: Follicular development ↓).

Answer Choices:

Answer:\n4 → 3 → 1 → 2

 

Question: TY (68-year-old male) is on phenobarbital, inhaled budesonide, methotrexate, etc. Which meds may contribute to osteoporosis risk? (Select ALL)

Answer Choices:\n\nA. Ibuprofen B. Phenobarbital C. Inhaled budesonide D. Methotrexate E. Glipizide

Answer:\nB, C, D

 

Question: Which agent binds the estrogen receptor and marks it for proteolytic degradation?

Answer Choices:\n\nA. Fulvestrant (Faslodex®) B. Letrozole (Femara®) C. Exemestane (Aromasin®) D. Tamoxifen

Answer:\nA

 

Question: A woman’s last menstrual period was 9 months ago; she is in which stage?

Answer Choices:\n\nA. Menopause B. Premenopause C. Postmenopause D. Perimenopause

Answer:\nD

 

Question: When is a drug holiday recommended in a postmenopausal woman with moderate fracture risk on alendronate, stable BMD, no fractures?

Answer Choices:\n\nA. After 3 years B. After 5 years C. After 6 years D. After 2 years

Answer:\nB

 

Question: Which should be discussed about NuvaRing® interactions & adverse events?

Answer Choices:\n\nA. It may increase thromboembolic risk (though absolute risk is small) B. NuvaRing® exposes women to 60% more estrogen than COCs C. Common outpatient antibiotics reduce its effectiveness D. Seek immediate help for “PAINS”

Answer:\nA